[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620547":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":61,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":10,"maxAge":10,"enrollmentInfo":72,"targetDuration":75,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ivonescimab neoadjuvant therapy group",null,"Patients in this group will receive ivonescimab as neoadjuvant therapy",[13],"Drug: Ivonescimab",{"label":15,"type":10,"description":16,"interventionNames":17},"PD-1 inhibitors neoadjuvant therapy group","Patients in this group will receive other PD-1 inhibitors as neoadjuvant therapy",[18],"Drug: PD-1 Inhibitors",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Ivonescimab","Patients in the experimental group will receive ivonescimab as neoadjuvant therapy.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"PD-1 Inhibitors","Patients in the positive control group will receive PD-1 inhibitors monotherapy as neoadjuvant treatment.",[15],[30],{"name":31,"affiliation":5,"role":32},"Fan Yang","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Hao Li","CONTACT","+86 13051713494","lihao_pkuhsc@163.com",{"name":40,"role":36,"phone":41,"phoneExt":10,"email":42},"Huiming Han","+86 18801398013","huimingpkuhsc@163.com",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":59,"role":36,"phone":60,"phoneExt":10,"email":42},"Fan Yang, MD.","010-88326650",{"type":32,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yang Fan, MD","Vice President","100620547","mechanism-of-enhanced-efficacy-of-ivonescimab-in-neoadjuvant-therapy-for-non-small-cell-lung-cancer-100620547",false,"NCT07359040","Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","Inclusion Criteria:\n\nPatients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy.\n\nExclusion Criteria:\n\n1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;\n2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);\n3. Pregnancy or lactation;\n4. Insufficient sample quality;\n5. Severe organ dysfunction (e.g. cardiac or renal insufficiency);\n6. Other judgments by the Investigator that the patient should not participate in the study.","ALL",{"count":73,"type":74},80,"ESTIMATED","5 Years","OBSERVATIONAL","This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1\u002FVEGF bispecific antibody, with those of conventional PD-1 inhibitors. Beyond evaluating its direct therapeutic benefits, this research also seeks to elucidate the potential mechanisms underlying the enhanced efficacy of Ivonescimab. Additionally, the study will conduct secondary exploratory analyses, including the identification and validation of predictive and prognostic biomarkers, as well as multi-omics profiling to investigate the molecular mechanisms of action. Collectively, these efforts aim to provide comprehensive experimental data to support the rational clinical application of Ivonescimab and the development of precision medicine strategies for NSCLC.",[79,80,26,81],"Non-Small Cell Lung Cancer","Neoadjuvant Therapy","Immunotherapy",[83,22,79],"Neoajuvant therapy","2026-06-02",{"date":86,"type":87},"2026-06-03","ACTUAL",{"date":89,"type":87},"2025-07-01",{"date":91,"type":74},"2027-10-30",{"name":5,"class":6},1]